Genemarkers will utilize a
pharmacogenomic testing panel and a custom screening panel to help researchers study how genetic data may improve opioid prescribing for chronic
pain and
medication-assisted treatment of opioid use disorder, and potentially identify patients at a greater risk for addiction.
